John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

Recommandations sur le traitement de l’infection à Helicobacter pylori chez l’adulte Volume 24, numéro 2, Février 2017

  • [1] Lamarque D., Burucoa C., Courillon-Mallet A. Révision des recommandations françaises sur la prise en charge de l’infection par Helicobacter pylori. Hépato-Gastro et Oncologie Digestive. 2012;19:475-502.
  • [2] Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017 ; 66 : 6-30.
  • [3] Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016 ; 151 : 51-69.e14.
  • [4] Fischbach L.A., van Zanten S., Dickason J. Meta-analysis : the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004;20:1071-1082.
  • [5] Graham D.Y. Antibiotic resistance in Helicobacter pylori : implications for therapy. Gastroenterology. 1998;115:1272-1277.
  • [6] Thung I., Aramin H., Vavinskaya V. Review article : the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533.
  • [7] Loo V.G., Fallone C.A., De Souza E. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother. 1997;40:881-883.
  • [8] Dore M.P., Leandro G., Realdi G. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy : a meta-analytical approach. Dig Dis Sci. 2000;45:68-76.
  • [9] Raymond J., Lamarque D., Kalach N. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter. 2010;15:21-27.
  • [10] Megraud F., Coenen S., Versporten A. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42.
  • [11] Tankovic J., Lamarque D., Lascols C. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther. 2001;15:707-713.
  • [12] Duck W.M., Sobel J., Pruckler J.M. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons. United States. Emerg Infect Dis. 2004;10:1088-1094.
  • [13] De Francesco V., Margiotta M., Zullo A. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144:94-100.
  • [14] Molina-Infante J., Pazos-Pacheco C., Vinagre-Rodriguez G. Nonbismuth quadruple (concomitant) therapy : empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter. 2012;17:269-276.
  • [15] McMahon B.J., Hennessy T.W., Bensler J.M. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139:463-469.
  • [16] Malfertheiner P., Bazzoli F., Delchier J.-C. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy : a randomised, open-label, non-inferiority, phase 3 trial. The Lancet. 2011;377:905-913.
  • [17] Laine L., Hunt R., El-Zimaity H. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients : a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567.
  • [18] Malfertheiner P. Infection : Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7:538-539.
  • [19] Wenzhen Y., Yumin L., Quanlin G. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med Tokyo Jpn. 2010;49:1103-1109.
  • [20] Cosme A., Lizasoan J., Montes M. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. Helicobacter. 2016;21:29-34.
  • [21] Liou J.M., Chen C.C., Chang C.Y. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection : a multicentre clinical trial. J Antimicrob Chemother. 2013;68:450-456.
  • [22] Villoria A., Garcia P., Calvet X. Meta-analysis : high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-877.
  • [23] Graham DY. Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy : Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter 2016 ; 21 : 85-90.
  • [24] Graham D.Y., Shiotani A. Which Therapy for Helicobacter pylori Infection? Gastroenterology. 2012;143:10-12.
  • [25] Yuan Y., Ford A.C., Khan K.J. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.
  • [26] Calvet X., Garcia N., Lopez T. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603-609.
  • [27] Lascols C., Lamarque D., Costa J.M. Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J Clin Microbiol. 2003;41:4573-4577.
  • [28] Oleastro M., Menard A., Santos A. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol. 2003;41:397-402.
  • [29] Vallve M., Vergara M., Gisbert J.P. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication : a meta-analysis. Aliment Pharmacol Ther. 2002;16:1149-1156.
  • [30] Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol. 2001;15:413-431.
  • [31] Scott D., Weeks D., Melchers K. The life and death of Helicobacter pylori. Gut. 1998;43:S56-60. Suppl. 1
  • [32] Erah P.O., Goddard A.F., Barrett D.A. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice : relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5-12.
  • [33] Janssen M.J., Laheij R.J., de Boer W.A. Meta-analysis : the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2005;21:341-345.
  • [34] Furuta T., Ohashi K., Kamata T. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129:1027-1030.
  • [35] Sharara A.I. Rabeprazole : the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther. 2005;3:863-870.
  • [36] Tang H.-L., Li Y., Hu Y.-F. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens : a meta-analysis of randomized clinical trials. PloS One. 2013;8:e62162.
  • [37] Zhao F., Wang J., Yang Y. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication : a meta-analysis. Helicobacter. 2008;13:532-541.
  • [38] Padol S., Yuan Y., Thabane M. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies : a meta-analysis. Am J Gastroenterol. 2006;101:1467-1475.
  • [39] McNicholl A.G., Linares P.M., Nyssen O.P. Meta-analysis : esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414-425.
  • [40] Tokoro C., Inamori M., Koide T. Does pretreatment with proton pump inhibitors influence the eradication rate of Helicobacter pylori? Hepatogastroenterology. 2010;57:1645-1649.
  • [41] Graham DY, Lee Y-C, Wu M-S. Rational Helicobacter pylori therapy : evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014 ; 12 : 177-186-13.
  • [42] Molina-Infante J., Romano M., Fernandez-Bermejo M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:e1121-128.
  • [43] McNicholl A.G., Marin A.C., Molina-Infante J. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244-249.
  • [44] Essa A.S., Kramer J.R., Graham D.Y. Meta-analysis : four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118.
  • [45] Gisbert X., Calvet J.P. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34.
  • [46] Wu D.C., Hsu P.I., Wu J.Y. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010;8:e136-41.
  • [47] Huang Y.-K., Wu M.-C., Wang S.S. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis. 2012;13:232-238.
  • [48] Venerito M., Krieger T., Ecker T. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88:33-45.
  • [49] Katelaris P.H., Forbes G.M., Talley N.J. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication : The QUADRATE Study. Gastroenterology. 2002;123:1763-1769.
  • [50] Zheng Q., Chen W.J., Lu H. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis. 2010;11:313-318.
  • [51] Laine L. Is it time for quadruple therapy to be first line? Can J Gastroenterol. 2003;17:33B-35B. Suppl. B
  • [52] Luther J., Higgins P.D., Schoenfeld P.S. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection : Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73.
  • [53] Gene E., Calvet X., Azagra R. Triple vs. quadruple therapy for treating Helicobacter pylori infection : a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1143.
  • [54] Dore M.P., Maragkoudakis E., Pironti A. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter. 2006;11:52-55.
  • [55] Filipec Kanizaj T., Katicic M., Skurla B. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter. 2009;14:29-35.
  • [56] Lambert J.R., Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11:27-33. Suppl. 1
  • [57] Megraud F., Lamouliatte H. Review article : the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1333-1343.
  • [58] O’Morain C., Borody T., Farley A. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori : an international multicentre study. Aliment Pharmacol Ther. 2003;17:415-420.
  • [59] Malfertheiner P., Bazzoli F., Delchier J.-C. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy : a randomised, open-label, non-inferiority, phase 3 trial. Lancet Lond Engl. 2011;377:905-913.
  • [60] Delchier J.C., Malfertheiner P., Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177.
  • [61] Goddard A.F. Review article : factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998;12:1175-1184.
  • [62] Cooreman M.P., Krausgrill P., Hengels K.J. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother. 1993;37:1506-1509.
  • [63] Furuta T., Sugimoto M., Yamade M. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54:258-266.
  • [64] Liao J., Zheng Q., Liang X. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373-377.
  • [65] Liou J.-M., Lin J.-T., Chang C.-Y. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection : a randomised comparative trial with crossover design. Gut. 2010;59:572-578.
  • [66] Bogaerts P., Berhin C., Nizet H. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441-445.
  • [67] Marzio L., Coraggio D., Capodicasa S. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006;11:237-242.
  • [68] Miyachi H., Miki I., Aoyama N. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006;11:243-249.
  • [69] Cattoir V., Nectoux J., Lascols C. Update on fluoroquinolone resistance in Helicobacter pylori : new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents. 2007;29:389-396.
  • [70] Ducournau A., Bénéjat L., Sifré E. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect. 2016;22:715-718.
  • [71] Wu H.-H., Liu H.-Y., Lin Y.-C. Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli. J Microbiol Immunol Infect. 2016;49:424-429.
  • [72] Giannini E.G., Malfatti F., Botta F. Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. Dig Sci. 2005;50:1207-1213.
  • [73] Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Ther Adv Gastroenterol. 2011;4:103-114.
  • [74] Gisbert J.P., Castro-Fernandez M., Bermejo F. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101:243-247.
  • [75] Gisbert J.P., Morena F. Systematic review and meta-analysis : levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35-44.
  • [76] Saad R.J., Schoenfeld P., Kim H.M. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection : a meta-analysis. Am J Gastroenterol. 2006;101:488-496.
  • [77] Cheng H.C., Chang W.L., Chen W.Y. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter. 2007;12:359-363.
  • [78] Di Caro S., Franceschi F., Mariani A. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480-485.
  • [79] Yee Y.K., Cheung T.K., Chu K.M. Clinical trial : levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2007;26:1063-1067.
  • [80] Gisbert J.P., Bermejo F., Castro-Fernandez M. Second-line rescue therapy with levofloxacin after H. pylori treatment failure : a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103:71-76.
  • [81] Marin A.C., McNicholl A.G., Gisbert J.P. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861.
  • [82] Gisbert J.P., Calvet X. Review article : rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221.
  • [83] Gisbert J.P., Castro-Fernandez M., Perez-Aisa A. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941-947.
  • [84] Bhagat N., Read R.W., Rao N.A. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology. 2001;108:750-752.
  • [85] Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther. 2003;74:591-2-3.
  • [86] Van der Poorten D., Katelaris P.H. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther. 2007;26:1537-1542.
  • [87] Brogden R.N., Fitton A., Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:983-1009.
  • [88] Borody T.J., Pang G., Wettstein A.R. Efficacy and safety of rifabutin-containing “rescue therapy” for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:481-488.
  • [89] Gisbert J.P., Gisbert J.L., Marcos S. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22:1041-1046.
  • [90] Sagar P.S., Katelaris C.H. Utility of penicillin allergy testing in patients presenting with a history of penicillin allergy. Asia Pac Allergy. 2013;3:115-119.
  • [91] Gisbert J.P., Barrio J., Modolell I. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci. 2015;60:458-464.